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Abstract 
According to the World Health Organization, metabolic syndrome (MetS) can be defined as a pathological condi-
tion characterized by abdominal obesity, insulin resistance, hypertension, and hyperlipidemia. The incidence of MetS 
keeps rising, as at least 35% of the USA population suffers from MetS. One of the worst comorbidities of metabolic 
syndrome are cardiovascular diseases that significantly amplifies the mortality associated with this syndrome. There is 
an urgent need to understand the pathophysiology of MetS to find novel diagnosis, treatment and management to 
mitigate the MetS and associated complications. Altered circulatory adiponectin levels have been implicated in MetS. 
Adiponectin has numerous biologic functions including antioxidative, anti-nitrative, anti-inflammatory, and cardiopro-
tective effects. Being a pleiotropic hormone of multiple tissues, tissue-specific key signaling pathways of adiponectin 
will help finding specific target/s to blunt the pathophysiology of metabolic syndrome and associated disorders. The 
purpose of this review is to elucidate tissue-specific signaling pathways of adiponectin and possibly identify potential 
therapeutic targets for MetS as well as to evaluate the potential of adiponectin as a biomarker/therapeutic option in 
MetS.
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Introduction
Metabolic diseases including type 2 diabetes, obesity 
and other cardiovascular diseases are becoming alarm-
ing throughout the entire world among people of all age 
groups (~ 25% of all adults in the world) and causing mil-
lions of deaths each year [1]. In accordance with the prev-
alence of metabolic diseases like diabetes, cardiovascular 
diseases (CVDs) and other comorbidities are increasing 
day-by-day as well (relative risk of CVD is twofold in men 
and threefold in women) [2]. Thus, finding a common 
regulatory factor/mechanism which governs both meta-
bolic conditions and associated CVDs will provide new 
therapeutic options for managing them effectively. Adi-
ponectin, a 244 amino acid adipocytokines, qualifies this 
criterion. Adiponectin is encoded by the ADIPOQ gene 
in humans and is predominantly secreted by the adipo-
cytes of brown adipose tissue. There are a wide range of 
cells and tissues such as osteoblasts, parenchymal cells, 
myocytes, epithelial cells, hepatocytes, and placental tis-
sue that secret adiponectin in a small amount [3].
Four different forms of adiponectin have been iden-
tified in human plasma so far including low-molecu-
lar-weight (LMW) trimer, medium-molecular-weight 
(MMW) hexamer, high-molecular-weight (HMW) oli-
gomer and globular adiponectin (gAd) [4, 5]. Post trans-
lational modifications in adiponectin account for more 
than eight isoforms of adiponectin [6]. The molecular 
weight of LMW, MMW and HMW adiponectin are 
67  kDa, 140  kDa and 300  kDa respectively. LMW adi-
ponectin has a half-life of 32  min while MMW and 
HMW adiponectin have a half-life of 83 min. The plasma 
concentration of adiponectin in humans ranges from 2 
to 20  µg/ml, which is around 1000-fold higher than the 
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studies suggest that HMW adiponectin is the predomi-
nant form contributing to the regulation of different 
types of biological functions including insulin sensitiv-
ity, glucose uptake, and lipid metabolism [7]. Due to tis-
sue specific variability in the expression of adiponectin 
receptors and diversity of adiponectin isoforms, the tis-
sue specific adiponectin signaling mechanism also varies. 
In this review, we provide potential cellular mechanisms 
through which adiponectin exerts its role in a wide range 
of cell types.
Pleiotropic role of adiponectin
Adiponectin aided regulation of skeletal muscle function
Skeletal muscle contributes to almost half of the human 
body mass and is primarily known for its role in physi-
cal movement, posture, and breathing. However, skeletal 
muscle plays an active role in numerous metabolic path-
ways including carbohydrate, protein, and fat metabolism 
and storage of glucose and proteins [8]. Loss of skeletal 
muscle is associated with delayed recovery from illness 
and wound healing, decreased resting metabolic rate, 
higher chance of physical disability and higher health 
care costs [8, 9]. Findings from several studies showed 
that alterations of skeletal muscle mass (SMM) are asso-
ciated with cardiovascular health and even different 
muscle morphology [9, 10]. A recent finding from a pop-
ulation-based study demonstrated that skeletal muscle 
mass is inversely proportional to the incidence of CVD 
[9].
According to the earlier understanding, adiponectin 
acts on skeletal muscle cells, secreted only from the adi-
pose tissue as an endocrine manner. However, it has been 
recently discovered that adiponectin is also produced 
by the skeletal muscle cells, acting in an autocrine/par-
acrine manner through the stimulation of adiponectin 
receptor (AdipoR) 1 and AdipoR2 [11, 12]. Adiponectin 
plays protective roles in most of the tissue types. How-
ever, several studies implied that adiponectin plays both 
protective and destructive roles in different skeletal mus-
cle types. Adiponectin elevated intracellular  Ca2+ levels 
in cultured C2C12 myocytes, which has been reversed 
by siRNA-mediated knockdown of AdipoR1 [13], thus 
implying calcium-mediated contractility in muscle cells is 
regulated by adiponectin. Adiponectin-induced intracel-
lular  Ca2+ increases mitochondrial biogenesis in skeletal 
muscle via  Ca2+/calmodulin-dependent kinase (CaMK) 
activation followed by the activation of peroxisome pro-
liferator-activated receptor gamma coactivator 1-alpha 
(PGC1α) (Fig.  1) [14]. A study by Yoon et  al., showed 
that adiponectin treated differentiated C2C12 cells dose 
dependently increased the mRNA expression of Acyl-
CoA oxidase (ACO) and carnitine palmitoyltransferase 
1 (CPT1), two important genes for fatty acid oxidation 
in skeletal muscle, through the activation of peroxisome 
proliferator-activated receptor α (PPARα). This study also 
confirmed that adiponectin-induced activation of PPARα 
in C2C12 cells is mediated via the activation of AMP-
activated protein kinase (AMPK) and p38 mitogen-acti-
vated protein kinase (MAPK) which was confirmed by 
suppression of PPARα activity when C2C12 cells were 
co-treated with adiponectin and AMPK/p38 MAPK 
inhibitors. Additionally, adiponectin is shown to inhibit 
the activity of acetyl-CoA carboxylase (ACC), an endo-
plasmic reticular enzyme in eukaryotes that can inhibit 
mitochondrial β-oxidation, through AMPK-mediated 
pathway in C2C12 cells. Findings from this study suggest 
that adiponectin increases fatty acid oxidation in skeletal 
muscle cells through the activation of AMPK/MAPK/
PPARα signaling pathway (Fig. 1) [15].
Tibialis anterior muscle (TAM)-specific overexpres-
sion of both AdipoR1 and AdipoR2 increased phospho-
rylation of AMPK, protein kinase B (PKB/AKT) and 
extracellular signal-regulated kinase (ERK) and subse-
quently increased the expression of the insulin respon-
sive glucose transporter (GLUT)4 (Fig.  1). However, 
overexpression of VEGFR2 alone in TAM, increased the 
expression of PPARα and peroxisomal acyl-coenzyme 
A oxidase (ACOX)1, the first enzyme of the fatty acid 
β-oxidation (Fig.  1) [16]. Successive intravenous injec-
tions of AdipoRon, an agonist for AdipoR1 and AdipoR2, 
in C57BL/6J mice decreased the weight gain and mean 
muscle fiber cross-sectional area and the protein con-
tent in plantaris muscle (PLA), but not in soleus mus-
cle (SOL). Additionally, knockdown of AdipoR1 and/
or AdipoR2 in C2C12 myotubes rescued AdipoRon-
associated decrease in protein content in PLA, but not 
in SOL. However, AdipoRon administration significantly 
increased the phosphorylation of AMPK in both PLA 
and SOL [17]. By employing the adiponectin knockout 
(AdipoKO) mice, it has been demonstrated that adi-
ponectin is involved in muscle activity as these Adipo KO 
mice exhibited poor endurance exercise capacity com-
pared with their age-matched wild-type controls [6, 18]. 
High-fat diet (HFD)-induced diabetes mellitus in rodents 
impaired gastrocnemius muscle contractile parameters 
(e.g. peak twitch tension, peak tetanic tension and half 
relaxation time) by downregulating the gene expres-
sion of adiponectin and sarcoplasmic reticulum calcium 
ATPase (SERCA), a crucial factor of intracellular  Ca2+ 
homeostasis. However, adiponectin treatment in diabetic 
rats increased the expression of SERCA, GLUT4 and adi-
ponectin genes whereas it decreased the levels of serum 
glucose, insulin, HOMA index, triglycerides, and cho-
lesterol [19]. Also, adiponectin is shown to be associated 
with increased muscle regeneration and decreased pro-
teolysis which ultimately led to increased muscle mass 
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[20]. Sarcopenia, a pathological condition of progressive 
muscle loss in aging [21] or cancer [22], is negatively 
correlated with plasma adiponectin levels [23]. Serum 
adiponectin levels were significantly lower in a cohort 
of sarcopenic patients compared with their non-sarco-
penic controls [24]. There are contradictory findings to 
this notion; for instance, elevated adiponectin levels are 
positively correlated with sarcopenic males with cardio-
vascular disease (CVD) relative to non-sarcopenic males 
with CVD [25]. Plasma adiponectin levels were increased 
significantly in spinal and bulbar muscular atrophy 
patients compared to the healthy age-matched sub-
jects [26]. Adiponectin is also associated with increased 
translocation of fatty acids in skeletal muscle cells to fuel 
β-oxidation process via increased expression of CD36, a 
fatty acid transporter (Fig.  1) [4]. A significant decrease 
in mitochondrial biogenesis and function in gastrocne-
mius muscles by decreasing the expression of PPARα and 
PGC-1α [27] was observed in AdipoKO mice. The same 
study also showed that both type 1 (oxidative) and type 
2 (glycolytic) muscle fibers are reduced in the skeletal 
muscle tissues of adipoKO mice. Also, treatment with 
globular adiponectin decreased ROS formation in skele-
tal muscle cells [27]. Interactions between phosphotyros-
ine and an adaptor protein, with PH domain and leucine 
zipper (APPL)1, which is a downstream signaling protein 
in adiponectin receptors-mediated signal transduction 
pathways, play an important role in insulin-mediated 
signaling in skeletal muscle by activating insulin receptor 
substrate (IRS) 1/2 [28].
Sirtuin1 (SIRT1) plays an important role in fatty acid 
oxidation and mitochondrial biogenesis through PGC-1α 
Fig. 1 Role of adiponectin in skeletal muscle. Adiponectin-induced activation of AdipoR1/AdipoR2 and subsequent interaction with adapter 
proteins, APPL1/APPL2, enhance fatty acid oxidation through MAPK-PPARα-mediated expression and activation of ACOX1 and AMPK-NAD+/
NADH-mediated response of ACC. Activated AdipoR1/AdipoR2 also increase mitochondrial biogenesis through APPL1-SERCA-Ca2+-CaMKKβ 
or LKB1-AMPK-NAD+/NADH-SIRT1-mediated activation of PGC1α. Additionally, activation of adiponectin receptors enhances glucose uptake 
via APPL1-Rab5 or APPL1-AMP-AMPK-mediated translocation of GLUT4 as well as attenuation of Rheb-mTOR-S6K1-induced inhibition of insulin 
signaling
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acetylation and PPAR-α activation in skeletal muscle 
[29]. It is also shown that adiponectin-induced increase 
in intracellular  Ca2+ influx and activation of CaMKK, 
AMPK, and SIRT1 were decreased in muscle-specific 
AdipoR1 KO mice [30]. In skeletal muscle, adiponectin-
induced activation of tuberous sclerosis 1 (TSC1) inhib-
its the activity of Ras homolog enriched in brain (Rheb), 
a negative regulator of insulin signaling as it suppresses 
the activity of insulin receptor substrate-1 (IRS-1) (Fig. 1) 
[31, 32]. Thus, it can be summarized that adiponectin 
elicits its physiological and ameliorative function in skel-
etal muscles by modulating aforementioned signaling 
pathways.
Adiponectin aided regulation of vascular smooth muscle 
function
Vascular smooth muscle cells (VSMCs), key cells in 
the vessel walls that regulate blood pressure. Their dys-
function may lead to pathological conditions including 
hypertension, restenosis and atherosclerosis [33]. Adi-
ponectin is an anti-atherogenic and anti-inflammatory 
adipokine in atherosclerosis [34]. However, the mecha-
nisms underlying the effect of adiponectin on VSMCs 
are not clearly elucidated. AdipoR1 and AdipoR2 are 
shown to be expressed in cultured human VSMC line 
[35]. According to Ding et  al., treatment with HMW 
adiponectin is shown to induce human coronary artery 
VSMCs differentiation as dictated by the upregulation 
of contractile protein markers of VSMC differentiation, 
including smooth muscle myosin heavy chain, h-calde-
smon, calponin, and smooth muscle-α-actin [36]. They 
also showed that HMW adiponectin treatment repressed 
mechanistic target of rapamycin complex 1 (mTORC1) 
and forkhead box protein O4 (FoxO4) through the acti-
vation of AMPKα2 in human coronary artery VSMCs 
(Fig. 2) [36]. VSMCs also secret adiponectin to regulate 
VSMC contractile phenotype in a autocrine/paracrine 
manner, this is demonstrated in VSMCs isolated from 
mice [37]. Contrary to the previous findings, Zhang et al. 
reported that adiponectin treatment inhibits the prolif-
eration and migration of cultured human coronary artery 
VSMCs [38]. They also reported that adiponectin treat-
ment stimulates apoptosis by modulating mitofusin-2 
(MFN2)-mediated Ras-Raf-Erk1/2 signaling pathway 
(Fig. 2) [38]. Findings from these studies suggest that adi-
ponectin inhibits neointimal formation in pathological 
conditions where excessive proliferation and numbers of 
VSMCs are deleterious, through suppressing the prolif-
eration and migration as well as enhancing apoptosis of 
VSMCs.
A study aimed to determine the role of adiponectin and 
its receptors in angiotensin II (Ang II)-induced vascu-
lar injury [35]; the findings from the study suggest that 
adiponectin treatment significantly attenuated Ang II-
induced VSMCs migration and p38 phosphorylation [35]. 
Additionally, treatment with AdipoRon attenuated Ang 
II-induced hypertensive vascular hypertrophy and fibro-
sis [35]. Another study using rat aortic tissue showed that 
adiponectin pretreatment before Ang II challenge atten-
uated Ang II-mediated hypertrophic effect in VSMCs 
through the inhibition of RhoA/ROCK pathway and 
subsequent ROS formation (Fig. 2) [39]. Thus, it appears 
adiponectin works as a protective molecule in Ang II-
induced hypertension following vascular remodeling.
Adiponectin aided regulation of cardiac muscle function
Cardiomyocyte is the key cell type of the heart tissue, as 
it is responsible for cardiac contractility and relaxation, 
the primary function of the heart. Most cardiac dis-
eases including heart failure (HF), cardiomyopathy and 
myocardial infarction (MI) are directly associated with 
impaired contractile function/death of cardiomyocytes 
[40]. Metabolic diseases like obesity and type 2 diabetes 
mellitus (T2DM) are strongly associated with heart dis-
eases such as atherosclerosis, coronary artery disease 
(CAD), MI and HF [41]. Several studies in humans and 
rodents confirmed that obesity [42], T2DM [43], hyper-
tension [44], atherosclerosis [45], CAD [46], MI [47] and 
HF [46] are associated with reduced plasma adiponectin 
levels and/or impaired adiponectin signaling in target tis-
sues. Cardiomyocytes are known to secrete adiponectin 
in a paracrine/autocrine manner, although this level is 
relatively low compared with the levels produced by the 
adipose tissue [48, 49]. Several studies reported that adi-
ponectin receptors are expressed in human cardiomyo-
cytes, murine derived atrial cardiomyocytes and neonatal 
rat ventricular cardiomyocytes [48, 50]. Adiponectin is 
known to exert its cardioprotective role on cardiomyo-
cytes through the activation of AdipoR1 and AdipoR2 
[49]. Adiponectin improved contractility of cardiomyo-
cytes isolated from db/db obese mice through the activa-
tion of AdipoR1/AdipoR2 [51]. Cao et  al., revealed that 
globular adiponectin attenuated Ang II-induced atrial 
hypertrophy through the activation of AdipoR1/APPL1 
signaling pathway and subsequent decrease in NF-κB 
activation and translocation into the nucleus in rat atrial 
cardiomyocytes [52]. They also reported that activation 
of AdipoR1/APPL1 upregulated the expression and/or 
activation of downstream signaling molecules including 
PI3K, AMPK and NF-ĸB in rat atrial cardiomyocytes [52]. 
SiRNA-mediated knockdown of AdipoR1 and/or Adi-
poR2 attenuated C1q tumor necrosis factor-alpha-related 
protein 9 (CTRP9)-mediated inhibition of ROS forma-
tion and increased apoptosis of cardiomyocytes in H9C2 
rat cardiomyoblast cell line [53]. Cardiomyocyte-specific 
PPARγ overexpressing mice showed a significant increase 
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in adiponectin production in an autocrine manner and 
subsequently protect cardiomyocytes from hypertrophy 
that dictates PPARγ a downstream signaling molecule of 
adiponectin expression in cardiomyocytes [54]. Another 
study concluded that exenatide, a 39-amino-acid pep-
tide and a synthetic version of exendin-4 hormone which 
is used as an anti-diabetic medication, prevented the 
apoptosis of isolated cardiomyocytes from diabetic rats 
via upregulating the expression of adiponectin, APPL1, 
p-AMPK and PPARα and downregulating the expres-
sion of NFκB [55]. Pretreatment with recombinant rat 
adiponectin before Ang II stimulation, promoted AMPK 
phosphorylation and inhibited ERK1/2 activation in 
neonatal rat ventricular myocytes (NRVMs) [56]. Adi-
ponectin treatment is shown to upregulate the expres-
sion of miR-133a, a key regulator of cardiac hypertrophy 
through AdipoR1/AMPK activation and ERK1/2 inhi-
bition in NRVMs [56]. Adiponectin has been shown 
to induce actin cytoskeleton remodeling to mobilize 
GLUT-4 mediated increased glucose uptake through the 
activation of APPL1/Rho/Rho-associated protein kinase 
(ROCK) signaling pathway in neonatal rat cardiomyo-
cytes (Fig. 3) [57]. Adiponectin promotes the activation of 
AdipoR1/APPL1/AMPKα2 signaling and inhibits acetyl-
CoA carboxylase (ACC) activity through phosphoryla-
tion and subsequently increases fatty acid oxidation in rat 
Fig. 2 Role of adiponectin in VSMC. Adiponectin enhances apoptosis and inhibits the proliferation of VSMCs through AdipoR1/dipoR2-mediated 
activation of MFN2-Ras-Raf-Erk1/2 signaling pathway in pathological condition. Adiponectin-induced activation of AMPK attenuates 
mTORC1-S6K1-mediated inhibition of insulin signaling and subsequently increases protein synthesis and attenuates FoxO4-mediated inhibition of 
VSMC proliferation in atherosclerosis. Adiponectin-induced production of endothelial NO also diffuses into the VSMCs and subsequently inhibits the 
activation of RhoA protein, an upstream factor that induces VSMC hypertrophy through ROCK-Cofilin-mediated increase in F-actin/G-actin ratios 
following the formation of ROS
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cardiomyocytes (Fig.  3) [58]. Additionally, adiponectin 
increases cluster of differentiation 36 (CD36) transloca-
tion and fatty acid uptake as well as AKT phosphoryla-
tion and insulin-induced glucose transport in primary 
cardiomyocytes (Fig.  3) [58]. Adiponectin-induced acti-
vation of AMPK has been shown to share its cardiopro-
tective role with Sirtuin 1 (Sirt1). A recent study showed 
that adiponectin-induced activation of AMPK/Sirt1 
signaling contributes to the preconditioning of myocar-
dial ischemia–reperfusion (IR) injury in rats [59]. Adi-
ponectin treatment is shown to induce the activation of 
ceramidase (CDase) and subsequently prevents apoptosis 
of isolated ventricular cardiomyocytes from obese mice 
through the degradation of ceramides [60]. Adiponectin 
has been shown to involve myocardial ischemic postcon-
ditioning (IPo)-mediated cardioprotection against myo-
cardial ischemia–reperfusion (IR) injury in rodents via 
both AMPK-dependent nuclear and AMPK-independent 
mitochondrial signal transducer and activator of tran-
scription (STAT)3 activation [61]. Adipo KO mice exhib-
ited enhanced myocardial apoptosis, infract size, levels of 
nitric oxide (NO), inducible nitric oxide synthase (iNOS), 
superoxide, and their cytotoxic reaction products, perox-
ynitrite, in cardiac tissues [62]. On the other hand, adi-
ponectin treatment markedly decreased iNOS protein 
expression and NO/superoxide production, blocked per-
oxynitrite formation and attenuated the progression of 
atherosclerotic lesions in carotid artery of ApoE−/− mice 
Fig. 3 Adiponectin signaling in Cardiomyocyte. Adiponectin-induced activation of AdipoR1 or AdipoR2, triggers LKB1-mediated activation 
of AMPK that prevents cardiac hypertrophy by inhibiting Nuclear factor-κB (NF-ĸB), reactive oxygen species (ROS) formation and extracellular 
signal-regulated kinase (ERK) and by stimulating fatty acid oxidation. Adiponectin-induced AMPK also prevents inflammation-mediated myocardial 
infarction through the activation of endothelial nitric oxide synthase (eNOS) as well as prevents diabetic cardiomyopathy via increasing fatty 
acid oxidation. Adiponectin-induced activation of ceramidase (CDase) prevents apoptosis of cardiomyocytes and subsequent development 
of cardiac hypertrophy through the degradation of ceramides. Activated AdipoR1/AdipoR2 prevents diabetic cardiomyopathy through 
APPL1-Rho-ROCK-mediated elevation of glucose uptake. Adiponectin-induced activation of Sphk-1-COX-2 cascade prevents myocardial infarction 
through the inhibition of TNF-α-mediated inflammation. Adiponectin-induced activation of PPARγ increases the transcription of adiponectin in 
cardiomyocytes
Page 7 of 18Roy and Palaniyandi  Cell Biosci           (2021) 11:77  
[63]. Intraperitoneal injection of a single dose of doxoru-
bicin, a cardiotoxic chemotherapeutic agent, was shown 
to significantly increase mortality and exacerbated left 
ventricular contractile dysfunction in adipo KO mice 
compared with age-matched doxorubicin-injected WT 
control [64] while adiponectin treatment was shown to 
ameliorate doxorubicin-mediated cardiotoxicity through 
Akt activation in NRVMs [64]. Induction of MI increased 
the cardiac levels of COX-2, a cardioprotective molecule, 
in wild type mice which was inhibited in adiponectin-
deficient mice. By using primary rat cardiomyocytes, adi-
ponectin was shown to increase COX-2 level, however 
to determine the signaling mechanism of whether adi-
ponectin augments COX-2 expression through a sphin-
gosine kinase-1 (SphK-1)-dependent pathway, the cardiac 
myocytes were pretreated with a SphK-1 inhibitor (SKI) 
followed by incubation with adiponectin or vehicle. It 
was found that adiponectin-mediated COX-2 upregula-
tion was diminished by 38% by preincubation with SKI. 
This was again confirmed by treating the cardiomyocytes 
with SiRNA of SphK-1 before treating with adiponectin 
as the results revealed that adiponectin-induced COX-2 
expression was decreased by SiRNA of SphK-1 by 43% 
compared to control RNA. Thus, it can be summarized 
that adiponectin activates sphingosine kinase-1 (SphK-
1)/COX-2 signaling in cardiomyocytes and thus contrib-
utes to the cardioprotection in myocardial inf arction 
(Fig. 3) [65, 66].
Adiponectin aided regulation of vascular endothelial cell 
function
The vascular endothelial cells (ECs) plays an indispen-
sable role in the cardiovascular system as they serve 
as a protective barrier between blood and vessel walls, 
as well as secrete a plethora of bioactive substances 
including vasoactive substances, enzymes, growth fac-
tors, cytokines and chemokines [67]. Impaired func-
tioning of the vascular ECs due to oxidative and shear 
stress, systemic hypertension, elevated levels of free 
fatty acids, pathogenic infection and intake of haz-
ardous chemicals can cause severe consequences in 
cardiovascular physiology including coronary artery 
disease (CAD), MI, cardiomyopathy, HF, atherosclero-
sis and arteriosclerosis [68]. One of the most impor-
tant factors that maintain cardiovascular homeostasis 
by controlling NO bioavailability is endothelial nitric 
oxide synthase (eNOS). The broad range of activities 
of eNOS in vascular ECs largely depends on posttrans-
lational modifications, including acylation, nitrosyla-
tion, phosphorylation, acetylation, glycosylation and 
glutathionylation [69]. Activation of eNOS-NO signal-
ing is associated with several cardiovascular functions 
including upregulation of EC angiogenesis, mitochon-
drial biogenesis, cell–cell communication, vasodilation 
and telomerase activity and downregulation of oxida-
tive stress, shear stress and infiltration of inflammatory 
cells [70]. Adiponectin has been shown to induce the 
phosphorylation of eNOS at  Ser633 [71] and  Ser1177 and 
generation of NO in human umbilical vein endothelial 
cells (HUVECs) through AdipoR1/R2-APPL1/AMPK-
mediated pathway (Fig. 4) [72]. Interaction between the 
heat shock protein (HSP) 90 and eNOS is required to 
produce NO in ECs which was confirmed by Amour 
et al. through a study where pharmacological inhibition 
of HSP90 activity attenuated Isoflurane-dependent NO 
production in human CECs (Fig. 4) [73]. Globular adi-
ponectin treatment dose-dependently increased NO in 
bovine aortic endothelial cells (BAECs). NO generation 
was elicited by stimulating the binding of HSP90 with 
eNOS and subsequently activation of PI3-AKT signal-
ing pathway to over activate eNOS. It was shown that 
pharmacological inhibition of HSP90 or PI3K in BAECs 
decreased globular adiponectin-mediated NO release. 
This globular adiponectin also increased endothelial 
cell-dependent vasorelaxation in rat aortic rings [74]. 
Treatment with globular adiponectin (5  μg/ml) inhib-
ited palmitate-induced ROS generation and subsequent 
induction of apoptosis in HUVECs. Using pharma-
cological interventions for cyclic AMP (cAMP) and 
AMPK, this study also showed that adiponectin inhib-
its the generation of ROS and subsequent induction of 
apoptosis in HUVECs through cAMP/PKA and AMPK 
mediated signaling pathway (Fig.  4) [75]. Transcrip-
tion factor NF-ĸB signaling plays a central role in the 
transcription of several proinflammatory cytokines and 
growth factors that are associated with the pathogen-
esis of several diseases including atherosclerosis [76]. 
Adenoviral transduction of adiponectin gene attenu-
ated the formation of atherosclerotic plaques in the 
aortic arch of  ApoE−/− mice through the inhibition of 
NF-ĸB pathway (Fig.  4) [77]. Treatment with globular 
adiponectin has been shown to increase human micro-
vascular ECs migration, proliferation and angiogenesis 
through upregulating the expression of proangiogenic 
factors including matrix metalloproteinase (MMP)-2, 
MMP-9 and VEGF. Adiponectin-induced upregulated 
expression of VEGF is mediated via the activation of 
AdipoR1, and MMP-2 and MMP-9 are mediated via 
the activation of both AdipoR1 and AdipoR2 [78]. Adi-
ponectin appears to play an important role in mito-
chondrial biogenesis in vascular ECs as evident by a 
study where Adipo KO mice downregulated the expres-
sion of regulatory proteins of mitochondrial biogen-
esis including PGC-1α, nuclear respiratory factor 1, 
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transcription factor A, Sirt3 and Sirt1 in pulmonary 
vascular ECs [79].
Adiponectin aided regulation of hepatocyte function
Hepatocytes, the major cell types in the liver that derived 
from parenchyma, contribute to the ~ 80% mass of the 
liver tissue and play indispensable roles in metabolism, 
detoxification, protein synthesis and activation of the 
innate immune system [80]. In hepatocytes, adiponec-
tin mainly contributes to the regulation of glucose and 
fat metabolism through an insulin-sensitizing effect. The 
role of adiponectin in healthy liver includes a decrease 
in gluconeogenesis, lipid biosynthesis, inflammation, 
and oxidative stress, and an increase in insulin sensitiv-
ity and fatty acid oxidation [81]. Adiponectin confers its 
biological effects in hepatocytes through the activation 
of AdipoR1 and AdipoR2 [82]. A review has summarized 
a large number of studies to report that adiponectin-
induced decrease in gluconeogenesis is regulated mainly 
through the activation of the liver kinase B1 (LKB1)/
AMPK axis in hepatocytes [83]. Adenoviral transduction 
of constitutively active form of AMPK has been shown 
to decrease the rate of gluconeogenesis through seques-
tering the expression and activities of two rate-limiting 
gluconeogenic enzymes, phosphoenolpyruvate carbox-
ykinase (PEPCK) and glucose-6-phosphatase (G6Pase) in 
primary rat hepatocytes [84, 85]. Transcriptional profil-
ing result from another study showed that treatment with 
5-aminoimidazole-4-carboxamide riboside (AICAR), an 
AMPK activator, upregulated the transcription of two 
Fig. 4 Adiponectin signaling in vascular endothelial cell. Adiponectin binds with its receptors, AdipoR1/AdipoR2, which in turn activate 
the downstream signaling molecules. Activation of AdipoR1 or AdipoR2 induces eNOS activation through PI3K/AKT signaling pathway and 
subsequently increases EC angiogenesis, mitochondrial biogenesis, cell–cell communication, vasodilation and telomerase activity, whereas it 
decreases oxidative stress, shear stress, infiltration of inflammatory cells and apoptosis. Adiponectin-induced activation of APPL1-cAPM-PKA-AMPK 
inhibits NF-ĸB-mediated expression of proinflammatory factors including plasminogen activator inhibitor-1 (PAI-1), interleukin 8 (IL-8), vascular cell 
adhesion molecule 1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1) and E-Selectin
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downstream targets of AMPK, early growth response 
1 (EGR1) and dual-specificity protein phosphatase 4 
(DUSP4) in AML12, H4IIE, and Fao cells. This finding was 
again confirmed by measuring mRNA and protein levels 
of EGR1 and DUSP4 in rat hepatoma cell lines, H4IIE 
and Fao. Using a reporter gene assay and real-time qPCR, 
this study further demonstrated that exogenous DUSP4 
inhibits the promoter activity and expression of both 
PEPCK and G6Pase in H4IIE cells [86]. Some reviews 
have summarized a large number of studies to report 
that adiponectin-induced activation of AMPK in hepato-
cytes is mediated via PLC/Ca2+/CaMKK signaling path-
way [82, 87]. Administration of adiponectin decreased 
fat accumulation in the liver of +Leprdb/+Leprdb (db/db) 
mice as well as in cultured Fao cell lines. This action of 
adiponectin is predominantly associated with the activa-
tion of the AdipoR1/LKB1/AMPK signaling pathway and 
subsequent downregulation of sterol regulatory element-
binding protein 1c (SREBP1c), a master regulator of fatty 
acid synthesis in the liver. The involvement of AdipoR1/
LKB1/AMPK signaling in adiponectin-induced down-
regulation of SREBP1c was further confirmed in LKB1 
KO (LKB1lox/lox) mice, where the absence of LKB1 res-
cued the inhibitory effect of adiponectin on SREBP1c 
expression [88]. However, a review demonstrated that 
adiponectin-induced AMPK activation in hepatocytes is 
much lower than other cell types [89]. Adiponectin low-
ers the rate of gluconeogenesis in hepatocytes not only 
through the activation of LKB1/AMPK signaling path-
way but also through other pathway/s independent of 
LKB1/AMPK activation [90]. Findings from this study 
were confirmed in mice with inducible hepatic dele-
tion of LKB1. This study showed that deletion of LKB1 
in the liver partially impaired glucose-lowering effects of 
adiponectin in  LKB1lox/lox mice. However, adiponectin-
induced downregulation of gluconeogenic and lipogenic 
gene expression including Ppargc1a, Glucose-6-phos-
phatase catalytic subunit, Phosphoenolpyruvate car-
boxykinase 1, SREBP1c, acetyl-CoA carboxylase (ACC) 
alpha, ATP citrate synthase, and fatty acid synthase 
(FAS) in and decreased hepatic glucose production was 
preserved in the liver of LKB1lox/lox mice [90]. Review 
with a large number of research findings demonstrated 
that adiponectin increases β-oxidation in hepatocytes 
through the activation of AdipoR1/LKB/AMPK signal-
ing pathway as well as increased activation of PPARα-
induced upregulation of acyl CoA oxidase (ACO) and 
UCP2. Adiponectin-induced inhibition of ACC-1 tran-
scription followed by the activation of carnitine palmi-
toyl transferase-1 (CPT-1) facilitates fatty acid transport 
into the mitochondria for β-oxidation (Fig. 5) [89]. Adi-
ponectin-induced activation of AdipoR1 or AdipoR2 
prevents hepatocellular ceramide accumulation through 
increased activation of ceramidase (CDase) and thereby 
may attenuate ceramide-mediated insulin resistance 
and hepatocyte apoptosis (Fig.  5) [60]. This finding was 
confirmed with increased CDase activity and decreased 
ceramide accumulation in liver-specific AdipoR1 and/
or AdipoR2 overexpressing mice liver [91]. Treatment 
with fibroblast growth factor 21 (FGF21), an important 
regulator of metabolism and energy homeostasis signifi-
cantly decreased ceramide accumulation in hepatocytes 
of obese mice through increasing the expression of adi-
ponectin, which leads to the restoration of euglycemia 
and reduced hyperlipidemia. The finding of this study 
was further confirmed when the effects of FGF21 were 
blunted in AdipoKO mice [92]. A study in AdipoKO 
mice has been shown to increase abnormal mitochon-
drial morphologies, decrease the oxidative activities of 
mitochondrial respiratory chain (MRC) complexes as 
well as decrease the expression of mitochondrial uncou-
pling protein 2 (UCP2) in the liver tissues relative to their 
age-matched control (Fig. 5). In the same study, the role 
of adiponectin in liver mitochondria was further con-
firmed when adenovirus-mediated replenishment of adi-
ponectin in AdipoKO mice liver significantly decreased 
lipid accumulation, restored the oxidative activities of 
MRC complexes and reduced the formation of lipid 
peroxidation products compared with control mice. 
Although, there were no significant effects on hepato-
cellular mitochondrial biogenesis and ROS production 
in adiponectin replenished liver in AdipoKO mice [93]. 
Adiponectin is reported to ameliorate D-galactosamine/
lipopolysaccharide (GalN/LPS)-induced liver injury in 
KK-Ay obese mice. A study reported that GalN/LPS-
induced liver injury is associated with systemic eleva-
tion of aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT), two important biomarkers of 
liver damage, increased levels of systemic and hepato-
cellular TNF-α, and/or showed a high degree of lethality 
in KK-Ay obese mice. Intraperitoneal administration of 
adiponectin before GalN/LPS challenge, ameliorated the 
GalN/LPS‐induced elevation of systemic AST and ALT 
levels, systemic and hepatocellular TNF-α levels as well 
as a reduction in lethality in KK-Ay obese mice. Addi-
tionally, adiponectin pretreatment increased the expres-
sion of PPARα mRNA in the liver of obese mice (Fig. 5) 
[94]. A study in 47 NAFLD patients showed systemic 
elevation of TNF-α, monocyte chemoattractant protein 
(MCP)-1 and IL-6 levels and decrease in adiponectin lev-
els in both males and females [95]. Therefore, it can be 
surmised that adiponectin works as an anti-inflammatory 
molecule by lowering the hepatocellular proinflamma-
tory cytokine levels. Cumulative findings from a review 
demonstrated that adiponectin-induced activation of 
antioxidant enzymes, superoxide dismutase (SOD)1 and 
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catalase contribute to hepatoprotection through the inhi-
bition of ROS-mediated production of proinflammatory 
molecules and subsequent reduction of oxidative stress 
(Fig. 5) [96].
Adiponectin aided regulation of pancreatic islet function
Around 50–70% of the human pancreatic islets are β cells 
which are known to play a profound role in metabolism 
through the production, storage and secretion of insu-
lin and amylin, two major peptides that regulate glucose 
homeostasis in circulation [97]. Since the cell signal-
ing mechanism of adiponectin is associated mostly with 
insulin-dependent tissues, a handful of metabolic studies 
focus on the role of adiponectin in pancreatic islet cells. 
However, due to the lack of substantial findings, the role 
of adiponectin signaling in pancreatic α and β-cells are 
not completely known yet. Adiponectin exerts its biologi-
cal effect on pancreatic β-cells through the activation of 
both AdipoR1 and AdipoR2, although AdipoR1 predomi-
nantly expressed in β-cells and globular adiponectin has a 
higher affinity for AdipoR1 [98–100].
A study by Okamoto et al., showed that administration 
of full-length adiponectin facilitates insulin secretion 
from both isolated and intact pancreatic islet in C57BL/6 
mice by enhancing exocytosis of insulin granules without 
affecting ATP generation, membrane potentials, cytosolic 
Fig. 5 Role of adiponectin signaling in the liver. Binding of adiponectin with AdipoR1 activates AMPK via APPL1/LKB1 or APPL1/PLC/Ca2+/
CaMKK mediated signaling pathways. Activated AMPK subsequently inhibits the activities of PEPCK and G6Pase through the activation of EGR1 
and DUSP4, which leads to decreased gluconeogenesis. Activated AMPK also decreases lipid biosynthesis through inhibiting sterol regulatory 
element-binding transcription factor 1c (SREBP1c)-mediated transcription of acetyl-CoA carboxylase (ACC), FAS and stearoyl-CoA desaturase (SCD)1. 
Additionally, activated AMPK increases abnormality in mitochondrial morphologies and fatty acid oxidation via sequestering the inhibitory effect 
of ACC-1 on carnitine palmitoyltransferase (CPT)-1 activation. Independent of AMPK activation, adiponectin also increases insulin sensitivity 
through the activation of AdipoR1 or AdipoR2 following CDase-mediated degradation of ceramides. Upon activation of AdipoR2 with the binding 
of adiponectin, fatty acid oxidation increases through PPARα-induced activation of acyl-CoA oxidase (ACO) and uncoupling protein (UCP)2. 
Adiponectin-induced activation of AdipoR1 contributes to the activation of antioxidant enzymes, superoxide dismutase (SOD)1 and catalase which 
subsequently decreases oxidative stress via downregulating ROS production. Adiponectin also protects hepatocytes through the inhibition of 
ROS-mediated activation of proinflammatory molecules including TNF-α and MCP1
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 Ca2+ concentrations or activation status of AMPK. This 
study also showed that adiponectin-induced activa-
tion of AMPK inhibits glucose-stimulated lipogenesis 
in MIN6 beta cells (Fig.  6) [101]. Adiponectin treated 
isolated islets from rats for 24  h, increased the mRNA 
expression of PPARγ and pancreatic and duodenal home-
obox (Pdx)-1, a key transcription factor that regulates 
early pancreas formation as well as glucose-mediated 
insulin secretion from β-cells (Fig.  6) [102]. Treatment 
with globular adiponectin for 24 h prevented apoptosis, 
increased β-cell viability, upregulated the expression of 
insulin genes (Ins I and Ins II) and secretion of insulin as 
through the activation of AKT and ERK in both MIN6 
beta cells and isolated islets from mice. Findings from 
this study were further confirmed when the adiponectin-
induced decrease in apoptosis, increased β-cell viability, 
upregulation of insulin gene expression and secretion of 
insulin were prevented with the use of dominant-neg-
ative Akt, PI3K inhibitor and MEK inhibitor. This study 
also showed that adiponectin treatment upregulated the 
expression of transcription factors Pdx1 and MafA in 
isolated mouse islets (Fig. 6) [100]. According to Ye and 
Scherer, adiponectin overexpressing mice with induc-
ible acute β-cell ablation has been shown to regenerate 
pancreatic β-cells as well as mitigate local lipotoxicity by 
upregulating the transcription of two key transcription 
factors, hepatocyte nuclear factor 4α and PPARα [103]. 
Another study and a review by the same research group 
revealed that adiponectin induces fat tissues to uptake 
fat molecules from bloodstreams and subsequently low-
ers circulatory cholesterol levels in β-cell-deficient mice. 
This study also demonstrated that both insulin and adi-
ponectin double deficient mice died after developing 
hypercholesterolemia. Findings from the studies suggest 
that a lack of adiponectin in insulin-deficient mice aggra-
vates insulin-mediated lipoatrophy and hyperlipidemia to 
lethal levels [104, 105]. Contrary to this finding, a study 
showed that adiponectin (5 µg/ml) treated normal islets 
isolated from healthy mice had no significant effect on 
insulin secretion. Although, adiponectin (5 µg/ml) treat-
ment inhibited insulin secretion in islets isolated from 
insulin resistant mice at 2.8  mM glucose exposure but 
Fig. 6 Role of adiponectin signaling in pancreatic β-cell. Adiponectin-induced activation of its receptors, AdipoR1 or AdipoR2, increases insulin 
secretion by increasing the transcription of insulin gene (INS) through the upregulation of transcription factors pancreatic and duodenal homeobox 
(Pdx)1 and MafA as well as increasing exocytosis of insulin granules. Adiponectin decreases the rate of hyperglycemia and lipogenesis through the 
activation of AMPK. Adiponectin-induced activation of AMPK also increases fatty acid oxidation through the inhibition of acetyl-CoA carboxylase 
(ACC). Adiponectin-induced activation of both MEK-ERK1/2 and PI3-AKT signaling pathways increase β-cell viability and decrease β-cell apoptosis 
through the inhibition of IL-1β, IFN-γ, palmitate and hyperglycemia
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augmented insulin secretion at 16.7  mM glucose expo-
sure. Based on these findings, it can be concluded that 
dichotomous action of adiponectin on pancreatic islets is 
due to the lack of exact in vivo environments that mimic 
the underlying pathological conditions like obesity or 
insulin resistance [106].
Adiponectin aided regulation of bone function
There are three types of bone cells that contribute to the 
process of bone formation: osteoblasts, osteoclasts and 
osteocytes. Remodeling of the bone is governed by an 
intricate balance between osteoblast-mediated bone for-
mation and osteoclast-mediated bone resorption. When 
the balance leans toward osteoblast number/activity, it 
causes an increase in bone mineral density (BMD) by 
lowering the number of osteocytes. On the other hand, 
when the balance leans toward osteoclast number/activ-
ity, it causes a decrease in BMD by decreasing the num-
ber of osteocytes [107]. There are limited studies that 
determine the role of adiponectin in bone cells. BMD 
data from the lumbar spine (L1–L4 together) and the hip 
(femoral neck) in a cohort of 92 participants showed that 
circulatory adiponectin levels decreased significantly in 
older men (60–80  years) with decreased BMD 
(BMI > 27  kg/m2) compared to older men (60–80  years) 
with normal BMD (BMI < 27  kg/m2) [108]. A study in 
rabbits with mandibular osteodistraction (distraction 
rate = 2  mm/day) showed that intermittent administra-
tion of adiponectin (2  µg) into the distraction gap pro-
moted much greater bone formation, higher BMD and 
bone mineral content (BMC) compared with vehicle-
treated rabbits after six weeks [109]. Administration of 
adiponectin overexpressing adenovirus in the jugular 
vein of 8-week-old C57BL/6 J male mice showed signifi-
cantly larger trabecular bone volume compared with the 
vehicle-treated mice after 2  weeks. Additionally, treat-
ment with recombinant adiponectin attenuated mac-
rophage colony-stimulating factor/receptor activator of 
nuclear factor-κB ligand-induced differentiation of bone 
marrow stromal cells and human CD14-positive periph-
eral blood mononuclear cells (PBMCs) into osteoclasts as 
well as significantly reduced the resorption area of CD14-
positive PBMCs relative to the control in a dose-depend-
ent manner. Adiponectin-treated MC3T3-E1 osteoblasts 
significantly increased the mRNA expression of alkaline 
phosphatase (ALP), an important biomarker of osteo-
blast differentiation, and the matrix mineralization on 
day 12 and 18 compared with the control. Findings from 
this study suggest that adiponectin treatment decreases 
osteoclast differentiation and increases osteoblast differ-
entiation and bone mineralization [110]. Intracere-
broventricular administration of adiponectin increases 
serum epinephrine and norepinephrine levels as well as 
osteoclast numbers whereas increases trabecular bone 
mass as well as the number of osteoblasts in both WT 
and adiponectin-KO mice. Additionally, central adminis-
tration of adiponectin significantly increased some neu-
ropeptides including hypothalamic tryptophan 
hydroxylase 2 (TPH2) and 5-hydroxytryptamine receptor 
2C (5-HTR2C). However, pharmacological stimulation of 
sympathetic activity with isoproterenol, a β-adrenergic 
agonist, attenuated adiponectin-mediated effects. These 
findings reveal that adiponectin increases bone mass 
through the suppression of sympathetic tone [111]. A 
study by Luo et al., showed that sustained release of adi-
ponectin for 4  weeks in hydroxyapatite (HA) implanted 
ovariectomized (OVX) rabbits significantly increased 
peri-implant osteogenesis compared with controls and 
short-term adiponectin treated groups. They also showed 
that sustained release of adiponectin in rabbit mature 
osteoclast culture significantly decreased the levels of 
tartrate-resistant acid phosphatase and F-actin, two 
important histochemical markers of osteoclasts, and 
eventually decreased the activity of osteoclasts compared 
to controls as well as short-term adiponectin treatment 
[112]. Adenovirus-mediated transfection of adiponectin 
in rat bone mesenchymal stem cells (BMSCs) signifi-
cantly increased the expression of AdipoR1 and AdipoR2. 
Treatment with adiponectin for 12  h significantly 
increased the mRNA expression and protein levels of 
β-catenin and cyclinD1, two important factors in Wnt/β-
catenin signaling in cultured BMSCs. Adiponectin treat-
ment for 3 and 7 days significantly increased the mRNA 
expression of some osteogenic genes including ALP, oste-
ocalcin (OCN), bone morphogenetic protein-2 (BMP-2) 
and runt-related transcription factor-2 (RUNX2) in cul-
tured BMSCs. Additionally, endogenous expression of 
adiponectin via intramuscular adenoviral delivery signifi-
cantly increased the expression/activation of OCN, BMP-
2, RUNX2 and ALP in isolated rat BMSCs (Fig.  7). 
Findings from this study suggest that adiponectin inhibits 
osteoclast-mediated bone resorption, increases osteo-
blast-mediated bone formation, and subsequently 
improves bone density [113]. A study by Huang et  al., 
showed that adiponectin treatment increased the mRNA 
expression and protein levels of BMP-2, an important 
factor for bone remodeling, in both cultured human oste-
oblast-like cell lines including hFOB and murine primary 
osteoblastic cells. They confirmed the involvement of 
AdipoR1 in adiponectin-mediated BMP-2 expression as 
adiponectin treated osteoblast significantly increased the 
mRNA expression of AdipoR1. This finding was further 
confirmed when AdipoR1 siRNA treatment abolished 
adiponectin-induced expression of BMP-2 in the hFOB 
cell line. They also confirmed the involvement of AMPK, 
p38 and NF‐κB in adiponectin-induced BMP-2 
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expression when treatment with specific pharmacologi-
cal inhibitors and siRNA blunted the effect of adiponec-
tin in BMP-2 expression in osteoblasts. Findings from 
this study suggest that adiponectin-induced upregulation 
of BMP-2 in osteoblasts is carried out through the activa-
tion of AdipoR1/AMPK/p38/NF-ĸB signaling pathway 
(Fig.  7) [114]. Another study showed that adiponectin-
treated mesenchymal stem cell (MSC) line C3H10T1/2 
and mouse PBMCs significantly increased the mRNA 
expression of ALP, OCN, OPN and type 1 collagen. This 
study also showed that adiponectin treatment for 3 h sig-
nificantly increased the mRNA expression and protein 
levels of cyclooxygenase (COX)-2, an important marker 
for osteoblast differentiation, as well as increased the lev-
els of prostaglandin  E2 (PGE2), the product of COX2, in 
C3H10T1/2 and mouse primary bone marrow cells. Adi-
ponectin treated C3H10T1/2 cells also increased the 
mRNA expression of c‐Jun, an important transcriptional 
activator of COX2 promoter, and ChIP assay deciphered 
the involvement of c-Jun in COX2 promoter activity. 
Additionally, adiponectin increased the phosphorylation 
of c-Jun through the activation of p38 MAPK as con-
firmed by kinase assay when adiponectin treatment aug-
mented the phosphorylation of both p38 MAPK and 
c-Jun. This finding was further confirmed by decreased 
phosphorylation of c-Jun when C3H10T1/2 cells were 
co-treated with p38 MAPK inhibitor. During osteogene-
sis, adiponectin exerts its role in MSC through the acti-
vation of AdipoR1, which was confirmed by decreased 
phosphorylation of p38 MAPK and COX2 expression 
when C3H10T1/2 cells were treated with AdipoR1 
siRNA. Adiponectin-induced upregulation of BMP-2 is 
also mediated through the activation of COX2 which was 
confirmed by decreased expression of BMP-2 when 
Fig. 7 Role of adiponectin in bone marrow-derived stem cells. Adiponectin increases osteoblast differentiation through AdipoR1-AMPK-P38-NF-ĸB 
signaling pathway-mediated expression and activation of COX-2. Adiponectin-induced activation of P38 also contributes to osteoblast 
differentiation through the activation of JNK. Adiponectin signaling increases osteogenesis through the activation of Wnt/β-cat-mediated 
expression of osteogenic genes including OCN, BMP-2, RUNX2 and ALP. Adiponectin-induced activation of AdipoR1-CK2-SMAD1/5/8 upregulates 
the transcription and activation of SDF-1 and subsequently increases the migration and recruitment of BMSCs
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C3H10T1/2 cells were co‐treated with COX2 inhibitor. 
Findings from this study revealed that adiponectin aug-
mented osteoblast differentiation through AdipoR1/p38 
MAPK/c-Jun-mediated transcription of cyclooxygenase 
(COX)-2 and subsequent upregulation of BMP-2 in mes-
enchymal progenitor cell (Fig. 7) [115]. To study the role 
of adiponectin in osteoblast retention ability within the 
bone marrow or at the injured bone site, Yu et al., showed 
that primary BMSCs isolated from 6‐week‐old  APN−/− 
mice decreased the expression of stromal cell-derived 
factor (SDF)-1 that mediates the retention and mobiliza-
tion of stem cells. They also found that adiponectin 
(10  µg/ml) treated BMSCs isolated from WT mice 
increased MMP9 mRNA expression around tenfold and 
subsequently increased their migration. Additionally, the 
study revealed that systemic administration of adiponec-
tin is shown to improve calvarial bone defects in DIO 
mice after 14 days. Also, they confirmed the involvement 
of SMAD1/5/8 activation in adiponectin-induced SDF-1 
upregulation by repressing the expression of SDF-1 when 
MC3T3‐E1 cells were co-treated with adiponectin and 
SMAD1/5/8 inhibitor. Furthermore, they deciphered that 
adiponectin‐dependent Smad1/5/8 phosphorylation 
depends on the interaction between AdipoR1 and casein 
kinase II (CK2). Findings from this study suggest that 
adiponectin increases retention and mobilization of 
BMSCs and subsequently increases bone regeneration 
through AdipoR1/CK2/SMAD1/5/8-mediated upregula-
tion of SDF-1 (Fig. 7) [116].
Adiponectin as a biomarker and a therapeutic 
target
Studies in both humans and animals show that circula-
tory adiponectin levels are negatively correlated with 
various pathological conditions including CVDs, T2DM, 
obesity, insulin resistance, NAFLD, atherosclerosis, car-
diomyopathy and HF [117]. Decreased levels of circula-
tory adiponectin are associated with a greater risk of 
morbidity and mortality in patients with CVDs, whereas 
increased circulatory adiponectin levels are cardiopro-
tective [117]. A cohort study showed that elevated levels 
of circulatory adiponectin are associated with a reduced 
risk of developing T2DM and subsequent reduction in 
cardiovascular risk [118]. Consistent with this finding, 
the cardioprotective role of adiponectin is also revealed 
by other studies where chronic low levels of circulatory 
adiponectin is associated with the development of MI 
and subsequent development of cardiovascular complica-
tions in both men and women [119]. Contrary to these 
findings, other studies reported that hyperadiponectine-
mia is associated with increased risk of HF and acute 
coronary syndrome in both men and women [120] as 
well as increase the severity of post-stroke outcomes 
[121]. NAFLD patients with advanced hepatic fibrosis 
have shown a reduction in circulatory adiponectin levels 
[122, 123]. Additionally, decreased serum adiponectin 
levels are inversely correlated with insulin resistance in 
patients with NAFLD [124]. Contrary to these findings, 
other studies in humans showed that increased serum 
adiponectin levels are positively correlated with cirrhosis 
[125]. Elevated serum adiponectin levels are considered 
as a biomarker of renal dysfunction [126], impaired renal 
metabolic environment [127] and end-stage renal disease 
[128] in patients with CKD.
It is well-researched that pharmacological elevation 
of circulatory adiponectin levels can ameliorate obe-
sity-related MetS. Studies in both animals and humans 
showed that using PPARγ agonist including thiazoli-
dinediones (TZD), a diabetic medication, can increase 
the levels of circulatory adiponectin [129, 130]. Medici-
nal plant-derived natural compounds such as astraga-
loside II and isoastragaloside I were shown to alleviate 
hyperglycemia as well as improve glucose tolerance and 
insulin sensitivity through increasing the production of 
adiponectin in obese mice [131]. Extract from Zataria 
multiflora, a plant of the Lamiaceae family, is shown to 
increase PPARγ-mediated circulatory adiponectin levels 
and subsequent improvement of insulin sensitivity and 
reduced glucose levels in insulin-resistant rats [132]. A 
dietary supplement such as vitamin E increases plasma 
adiponectin mRNA expression and protein levels in 
mice through the activation of PPARγ signaling [133]. 
Additionally, adiponectin mRNA expression and pro-
tein secretion were elevated in 3T3-L1 cells after vitamin 
E treatment [133]. Treatment with Wy-14643, a PPARα 
agonist is shown to increase the mRNA expression of 
AdipoR1 and AdipoR2 in epididymal white adipose tis-
sue (EWAT) of obese diabetic mice [134]. Treatment 
with Rosiglitazone increased the mRNA expression of 
AdipoR1 and AdipoR2 in isolated ventricular myocytes 
from rats [50]. Expression of AdipoR1 and AdipoR2 
mRNAs also increased in Pioglitazone treated human 
skeletal muscle [135]. Administration of telmisartan, an 
angiotensin receptor blocker, is shown to upregulate the 
expression of myocardial adiponectin and AdipoR2 as 
well as abdominal aortic AdipoR1 in diabetic rats [136]. 
The administration of metformin, a well-established dia-
betic drug, is associated with the upregulation of Adi-
poR1 and AdipoR2 in skeletal muscle and AdipoR1 in rat 
EWAT [137].
Concluding remarks and future directions
Nowadays the molecular insights of adipocyte biol-
ogy and associated adipokines are gaining more atten-
tion towards the discovery of novel therapeutics for 
treating MetS and associated complications. Among 
Page 15 of 18Roy and Palaniyandi  Cell Biosci           (2021) 11:77  
all the adipokines characterized so far, adiponectin got 
more attention due to its pleiotropic role over the other 
adipokines. A vast majority of adiponectin research 
in humans and animals studied only the correlation 
between different diseased states and circulatory adi-
ponectin levels. However, the tissue-specific expression, 
as well as the cell signaling mechanism of adiponectin, 
are not well characterized so far. More research needs to 
be carried out in animal and human models to establish 
tissue-specific precise mechanisms of adiponectin in dif-
ferent diseased conditions.
Circulatory adiponectin plays important roles as a bio-
marker in MetS and associated CVDs and has cardiopro-
tective, insulin-sensitizing and direct beneficial metabolic 
effects. Therefore, pharmacological or genetic interven-
tions can be used to increase the levels of systemic adi-
ponectin in MetS and associated CVDs. Additionally, 
adiponectin-induced activation of AdipoR1/AdipoR2 
is associated with multiple signaling pathways in a wide 
range of cell types including skeletal muscle cells, cardio-
myocytes, vascular ECs, VSMCs, hepatocytes, pancreatic 
β-cells and BMSCs (Fig. 8). Discovering potential thera-
peutics that can modulate the tissue-specific expression/
activation of adiponectin and its receptors AdipoR1/Adi-
poR2 can pave the way to treat tissue-specific effects of 
MetS.
Most of the pharmacological approaches studied so far 
used to enhance the levels of circulatory adiponectin as 
well as PPARα/PPARγ-mediated increase in AdipoR1/
AdipoR2 expression in humans and rodents. However, 
there are several downstream targets of adiponectin 
signaling including AMPK, mTOR, PGC1α, RhoA and 
SMADs in different tissue types (Figs. 1, 2, 3, 4, 5, 6, and 
7) that can be used as therapeutic targets to modulate 
the tissue-specific activities of adiponectin in different 
pathological conditions. Caloric restriction and exercise 
training have already been proven as effective lifestyle 
interventions to elevate systemic adiponectin levels in 
patients with MetS. Therefore, simultaneous use of phar-
macological and lifestyle interventions can potentiate the 
elevation of circulatory adiponectin levels in MetS.
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